Clinical Trial Of The Effects Of Coenzyme Q10 Supplementation On Glycemic Control And Markers Of Lipid Profiles In Diabetic Hemodialysis Patients
Notes for this study:
|| (mg/dL). Mean and SD. Placebo: before 24±13, after 28±16. Intervention: before 27±16, after 26±13.
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 60 participants with diabetes on hemodialysis were allocated to take 120 mg of coq10 daily or placebo for 12 weeks.
There was a statistically significant decrease in insulin and an increase in insulin sensitivity. Significantly lower VLDL and triglycerides were found. There was a nonsignificant reduction in HbA1c and fasting glucose. with no notable difference for total cholesterol, LDL, and HDL.